Abstract
Background Context Recent work indicates no increased mortality risk with concurrent gabapentin and opioid use when using an active comparator control design. However, concurrent gabapentin and opioid prescriptions have been associated with greater risk of respiratory depression in some studies.
Purpose To compare the risk of respiratory events among Medicare enrollees with spine-related diagnoses treated with gabapentin + opioids vs those treated with tricyclic antidepressants (TCA) or duloxetine + opioids. We hypothesized that enrollees treated with gabapentin + opioids would have increased risk of adverse respiratory events compared to those treated with an active control + opioids.
Study Design/Setting Propensity score-matched cohort study with an incident user, active comparator (TCA/duloxetine) control design. The primary analysis included those who concurrently (within 30 days) filled ≥1 incident gabapentin + ≥1 opioid or ≥1 incident TCA/duloxetine + ≥1 opioid prescription.
Patient Sample U.S. Medicare beneficiaries with spine-related diagnoses 2017-2019. People treated with gabapentin + opioids (n=66,580) were matched on demographic and clinical factors to people treated with TCAs/duloxetine + opioids (n=66,580).
Outcome Measures Time to a composite respiratory outcome consisting of mechanical ventilation, intubation, respiratory failure, pneumonia, or acute respiratory distress syndrome.
Methods Cox proportional hazard regression was used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs).
Results Among 133,160 Medicare enrollees (median age 73.3 years; 66.7% female), 6089 (4.6%) experienced respiratory events before the end of follow-up. A total of 3297 (5.0%) of people who were treated with gabapentin + opioids (median initial dose/day of gabapentin was 338 mg) had respiratory events compared to 2792 (4.2%) of those treated with an active control + opioids. The increased risk in those treated with gabapentin + opioids was statistically significant after adjustment (HR 1.14; 95% CI 1.09, 1.20; p<0.0001). The most common respiratory events were pneumonia (3.5% of people in the gabapentin + opioids group versus 3.0% of people in the TCA/duloxetine + opioids group) and respiratory failure (2.2% in the gabapentin + opioids group versus 1.8% in the TCA/duloxetine + opioids group). Results were similar in analyses (a) restricted to ≤30-day follow-up and (b) that required ≥2 fills of each prescription.
Conclusions While recent work has indicated no increased mortality risk with concurrent gabapentin and opioid use, the current findings suggest clinicians should exercise caution in prescribing gabapentin to people experiencing pain who are also being treated with opioids, due to the potentially increased risk of respiratory events.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the University of Washington Clinical Learning, Evidence, And Research (CLEAR) Center for Musculoskeletal Disorders, Administrative, Methodologic and Resource Cores and NIAMS/NIH grant P30AR072572. The funding source had no role in the study design, collection, analysis and interpretation of the data, writing of the report, or the decision to submit this article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Washington Institutional Review Board waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This work was supported by the University of Washington Clinical Learning, Evidence, And Research (CLEAR) Center for Musculoskeletal Disorders, Administrative, Methodologic and Resource Cores and NIAMS/NIH grant P30AR072572. The funding source had no role in the study design, collection, analysis and interpretation of the data, writing of the report, or the decision to submit this article for publication.
Competing Interests: The authors report no conflicts of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
